Endo International PLC  

(Public, NASDAQ:ENDP)   Watch this stock  
Find more results for ENDP
-0.31 (-0.46%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 66.45 - 67.53
52 week 36.17 - 82.16
Open 67.11
Vol / Avg. 0.00/1.55M
Mkt cap 10.15B
P/E     -
Div/yield     -
EPS -8.93
Shares 152.26M
Beta 1.24
Inst. own 94%
Jul 31, 2014
Q2 2014 Endo International PLC Earnings Release - 9:30AM EDT - Add to calendar
Jul 31, 2014
Q2 2014 Endo International PLC Earnings Conference Call - 8:30AM EDT - Add to calendar
Jun 10, 2014
Endo Health Solutions Inc. Annual Shareholder Meeting
May 21, 2014
Endo International PLC at UBS Global Healthcare Conference - Webcast
May 13, 2014
Endo International PLC at Bank of America Merrill Lynch Health Care Conference - Webcast
May 1, 2014
Q1 2014 Endo Health Solutions Inc. Earnings Release
May 1, 2014
Q1 2014 Endo International PLC Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -73.78% -20.46%
Operating margin -102.04% -14.77%
EBITD margin - 35.98%
Return on average assets -21.86% -8.15%
Return on average equity -101.57% -66.98%
Employees 3,371 -
CDP Score - -


Glandore Business Centres No. 33 Fitzwilliam Square, Dublin 2
+353-1-6698559 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Endo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company's subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.